SYNERGY

synergy vs XIENCE

Theoretical Advantages Translated into Worst Clinical Outcomes: Synergy vs. Xience

New data from a real-world registry soon to be published in J Am Coll Cardiol Intv suggest that Synergy (a thin-strut everolimus-eluting stent with a biodegradable polymer) is associated with a higher risk of acute stent thrombosis when compared with classic Xience (a thicker-strut everolimus-eluting stent with a durable polymer). At 12 months, there was<a href="https://solaci.org/en/2019/09/10/theoretical-advantages-translated-into-worst-clinical-outcomes-synergy-vs-xience/" title="Read more" >...</a>

dia-3-imagenes-consistent-compressor

EuroPCR 2018 | Consistent CTO Study: Rechanneling with Current Techniques and SYNERGY Stents

This observational study included 231 patients from 6 sites who presented chronic total occlusions and underwent rechanneling procedures using currently available techniques, which were successful in 90% of all cases (210 patients). All patients who underwent successful rechanneling received a SYNERGY stent and most of them underwent intravascular ultrasound (90.5%). There was only 1 patient lost to clinical follow-up<a href="https://solaci.org/en/2018/05/31/europcr-2018-consistent-cto-study-rechanneling-with-current-techniques-and-synergy-stents/" title="Read more" >...</a>

Registro Sueco con stent SYNERGY: por primera vez stent probado en angioplastia primaria

EuroPCR 2018 | Swedish Registry on the SYNERGY DES: tested in primary PCI for the first time

The study included 36292 consecutive patients undergoing acute myocardial infarction receiving PCI with the new generation stent SYNERGY (thin struts, bioresorbable polymer and everolimus eluting); 39.7% presented ST elevation MI. Kaplan-Meier curves at 2 years of patients receiving the SYNERGY vs patients receiving other drug eluting stents resulted very similar for thrombosis (0,69% vs 0,81%,<a href="https://solaci.org/en/2018/05/31/swedish-registry-on-the-synergy-des-tested-in-primary-pci-for-the-first-time/" title="Read more" >...</a>

synergy_stent

EVOLVE II: Diabetes Substudy: Results at 3 Years after the SYNERGY Stent in Diabetics

Courtesy of SBHCI Diabetic patients have worse evolution after coronary PCI. Drug eluting stents with bioresorbable polymers were designed to facilitate arterial healing, and reduce inflammation and late and very late thrombosis risk. &nbsp; This sub-study of diabetic EVOLVE II patients presents the 3 year outcomes of the SYNERGY stent. &nbsp; The EVOLVE II included<a href="https://solaci.org/en/2017/05/25/evolve-ii-diabetes-substudy-results-at-3-years-after-the-synergy-stent-in-diabetics/" title="Read more" >...</a>

synergy vs XIENCE

SYNERGY vs. XIENCE in Complex Real-World Patients

Courtesy of Dr. Guillermo Migliaro. Technological advancements in drug-eluting stents (DES) have shown significant improvement as regards the safety and efficacy of these devices. DES are considered to be the golden standard for the treatment of percutaneous coronary interventions. &nbsp; DES with permanent or durable polymers (DP) have been associated with local inflammatory reactions and<a href="https://solaci.org/en/2017/04/01/synergy-vs-xience-in-complex-real-world-patients/" title="Read more" >...</a>

IAM y múltiples vasos, ¿podemos realizar un solo procedimiento?

AMI and Multivessel Disease: Can We Perform a Single Procedure?

Percutaneous coronary intervention (PCI) is considered the treatment of choice in ST-segment elevation myocardial infarction (STEMI). However, it is widely acknowledged that, in many cases, there are significant lesions in other coronary arteries. Previous randomized studies have shown that complete revascularization in a second procedure is more beneficial than intervention only in the culprit artery.<a href="https://solaci.org/en/2023/09/19/ami-and-multivessel-disease-can-we-perform-a-single-procedure/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study

In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of the worst possible outcomes in terms of left ventricular remodeling, infarct size, ejection fraction and mortality, at long term.&nbsp; The TOTAL study (Routine Aspiration Thrombectomy with PCI Versus<a href="https://solaci.org/en/2023/07/17/no-reflow-after-primary-pci-in-stemi-an-angiographic-analysis-of-the-total-study/" title="Read more" >...</a>

synergy vs XIENCE

Diffuse Coronary Artery Disease: One-Year 48mm XIENCE Skypoint Outcomes

Long 48mm Stent XIENCE Skypoint in the treatment of diffuse CAD Long coronary artery lesions often involve complex decision making since they can be treated either with a long stent or with shorter overlapping stents. Both in registries and meta-analysis, the overlapping technique has been associated to increased target vessel revascularization and increased radioscopy time,<a href="https://solaci.org/en/2023/06/08/diffuse-coronary-artery-disease-one-year-48mm-xience-skypoint-outcomes/" title="Read more" >...</a>

¿En qué pacientes intentar la recanalización de una oclusión crónica total?

Should Total Occlusion Influence on Revascularization Strategy?

Success or failure of total occlusion (TO) revascularization does not affect mortality at 10 years, and this does not depend on revascularization strategy (PCI vs surgery) or location.&nbsp; The long-term clinical benefit of recanalization and PCI or TO artery bypass graft remains nuclear.&nbsp; This is a sub-study of the SYNTAXES (Synergy Between PCI With Taxus<a href="https://solaci.org/en/2021/03/19/should-total-occlusion-influence-on-revascularization-strategy/" title="Read more" >...</a>

Top